Pharmaceutical giant Johnson & Johnson is revolutionizing its drug discovery process through artificial intelligence, achieving a remarkable 50% reduction in the time required to identify promising treatment candidates, according to company executives.
Speaking at the Reuters Momentum AI event in New York on Monday, Chief Information Officer Jim Swanson revealed how the technology is transforming the company’s approach to finding new medications. While AI cannot yet independently discover and develop new drugs from start to finish, it’s proving invaluable for evaluating vast numbers of potential chemical compounds and biological treatments.
“That’s still a ways away, but we can optimize,” Swanson explained. “We’ve cut our lead optimization time in half.”
The New Jersey-headquartered healthcare company has strategically concentrated its AI efforts on essential operations, including product development powered by artificial intelligence, pharmaceutical research, and supply chain improvements.
“We’re trying to cure cancer,” Swanson emphasized. “We need every tool that we can leverage to be able to do that.”
Manufacturing processes have also benefited from AI implementation, with the technology helping determine optimal timing and temperature conditions for adding solvents during production.
Perhaps most dramatically, Johnson & Johnson has transformed its regulatory documentation workflow using artificial intelligence. Swanson noted that preparing clinical trial reports previously required between 700 and 900 hours of work.
That timeframe has been slashed from “700 hours to about 15 minutes,” Swanson reported.
Rather than viewing AI as a replacement for human workers, Swanson characterizes it as an enhancement to existing employee capabilities. The company currently employs approximately 4,000 information technology professionals.
“A software engineer isn’t getting replaced, now their role is expanding,” he noted. “Our focus continues to be on skills. These are ‘and’ skills, not ‘or’ skills.”
